Cochlear Implantation following Treatment for Medulloblastoma

✍ Scribed by John Thomas Roland Jr.; Tracey N. Liebman; Susan B. Waltzman

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 317 KB
• Volume: 119
• Category: Article
• ISSN: 0023-852X
• DOI: 10.1002/lary.20383

✦ Synopsis

Medulloblastoma, a primitive neuroectodermal tumor of the cerebellum, is the most common malignant tumor of the central nervous system (CNS) in children. Multi-modality treatment includes surgical excision, external beam radiation therapy and multi-agent chemotherapy. Otologic sequelae, such as chronic middle ear disease and hearing loss, are common in these patients and may result from both radiation and/or chemotherapy. Profound sensorineural hearing loss (SNHL) is a known complication of temporal bone chemoradiation and may ultimately render these patients eligible for cochlear implantation.